Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
Thanks Doc83.
This note puts a positive spin on our current state of play. It reiterates all the golden eggs in Synairgen's basket, which investors are well acquainted with by now. In addition, it highlights the company's aspiration for SNG001, should it eventually demonstrate successful mini-PII and PIII results. As investors, we must retain our belief in the potential of SNG001, although all must be disappointed with the current rate of progress.
I noted the following at the foot of today's statement:
"The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Cavendish Capital Markets Limited following completion of its own corporate merger."
Their statement, on behalf of a company that they represent, naturally aspires towards an optimistic forecast.
Synairgen has been in a state of suspension for 19 months. Nothing new has happened, and the company's share price has contracted to pre - CV19 levels. It is an aspiring University spinoff entity once again.
The cash reserve is solely from investor capital for the last Phase III trial. The company has not taken appropriate measures to reduce running costs. It has retained executives, who are unable to fulfil the roles for which they are appointed. Additionally, the salaries and benefit packages of the three most senior executives are too high for a company in a state of transition, with no discernible progress made this year.
Re-presenting the company's data at conferences is an unnecessary expense. The focus should be on getting Synairgen back on track. Should they continue to fail to show progress, as as present, they will run out of cash, and all investors will lose their capital. My only positive following today's announcement of further trial delay is that TFG Asset Management continue to hold. Perhaps the expertise at their disposal can discern more from the current situation than I am able to make of it, as things stand?
Alessandro Zamboni's lack of delivery has been a major disappointment. When the share price touched on 0.14p earlier this year, I contemplated selling my stock, albeit at a loss. On reflection, I subsequently perceived a period of consolidation, followed by a further rise, in line with the company's strategy. At first, I thought I had made the right call when the share price stabilised.
The recent change in sentiment has proved me to be totally wrong. I shall continue to hold my investment, as I believe that it will eventually deliver a good return. However, I intend to sell if and when I am reasonably in profit ( > 0.18p).
One puzzling question is why Mr. Zamboni is involved with RTOP? Surely his time and attention would have been better served towards bringing SYME to fruition?
That is a fair comment Professional. I have no idea of the context of the relationship between Synairgen and the pharmaceutical company. I gather that the information emerged from a conversation between a contributor to this forum and Simon Shaw, Synairgen’s Chairperson at the recent AGM. Mr. Shaw is unlikely to have volunteered that information if it hadn’t emerged from a serious discussion concerning a future partnership?
We were close to success at the last P3 trial. I believe that a change to a factor or factors in the conduct of the trial for example an earlier time span, or an increase in the patient number, might have resulted in a more favourable outcome for the company?
As things stand, I am more optimistic about future possibilities than was the case four months or so ago. You are correct in that the company are keeping trial details closely guarded until they have definitive information for investors. Having waited for some nineteen months, I am prepared to give this investment until the end of next Winter to see how the latest strategy develops? Following last year’s unfortunate failure, I am accepting that this is a binary investment, and remain hopeful of a recovery,
During the excellent feedback from the last AGM, it was mentioned that BP might be interested in our therapy, but that further supporting data would first be needed? I presume that the potential partners could well be GSK or Jansen - through the mutual link with Southampton’s CTU UNIVERSAL trial?
This is all tenuous for the time being, but what if further promising data were to emerge from Synairgen’s multiple P2 trials? Surely GSK and Jansen wouldn’t wait for a bidding war with other large entities? Either or both would want to secure an agreement as early and as cheaply as possible? Perhaps a recovery opportunity might yet be possible for Synairgen by early to mid 2024?
Synairgen have used data stratification to add several degrees of sophistication to their trial design in order to optimise the patient cohort for their trials.
Perhaps I am being too simplistic about this but didn’t the CEO’s comment years ago about SNG001 needing a fire to put out offer a useful start towards optimising patient selection? The failure in previous trials was due to there being no discernible difference between the outcomes between SNG001 and placebo treatment? By selecting patients with severe infections, surely this would offer SNG001 a better opportunity to demonstrate its efficacy?
Both Dr. Monk’s Synairgen - based presentation, and Southampton’s Clinical Trials Unit’s UNIVERSAL presentation, were given at around the same time. You are right in stating that the poster presentation of the UNIVERSAL trial outcomes would have been attended by Southampton CTU employees.
Out of SYME and into RTOP at its launch.
Out of RTOP and back into SYME today for a X3 increase in the investor’s original SYME shareholding.
Anyone who managed to do something similar to this is a very astute investor!
Thanks everyone for the updates regarding the recent presentations. IMHO all bodes well for the future, although our patience will need to endure for the present.
I will look at all this in detail when time avails. Has anyone taken on board whether Dr Monk added anything new to his poster presentation? Alternatively, did he present the summative Sprinter outcomes, perhaps leading to Synairgen’s multiple P2 mini trials ? Momentum is slowly building. Perhaps our patience will be rewarded at some point?
Meanwhile, will our next RNS announce the launch of the mini trials? Start of December at the earliest in my estimation?
IQAI have recently posted this on LinkedIn:
“ The quantitative DSC perfusion processing in FDA-cleared IB Neuro has been validated using a single dose of GBCA for 1.5T (already validated on 3T). The 50% reduction from the common double-dose approach (no preload) does not compromise image quality.”
News of applications of IB technology is proliferating. It is now a matter of time before a share price breakout. A buyout at > £100m is currently possible IMHO?
A recent IB message:
“A huge shout out to the @eaonc ACRIN/ECOG EAF151 team for completing trial accrual! EAF151 is the FIRST trial of its kind – with a goal to evaluate an advanced MRI biomarker for brain tumors. DSC perfusion imaging (@IQAI_IB's IB Neuro) was their choice.”
When I saw nine posts on this board a few minutes ago, I was hopeful of an interesting update. Instead, I discovered a trail of negativity countered by sensible pragmatism. Many thanks to jonnyboy33 especially, for your optimistic outlook, which I share.
The fact that any shareholder, including TFG, remains invested signifies that they believe in a future upside to this investment. There is little gained from whining about the share price, or apparent inaction from the company (which is very probably not the case).
Investors have a rough idea of the timeline involved in the company’s strategy. Unless there is a change in the latter, I do not expect an update until the end of this year at the earliest.
From yesterday's Reuters' article:
London Stock Exchange Group is looking into using blockchain to build what it described on Monday as "an end-to-end digital market ecosystem to raise and transfer capital across asset classes". Murray Roos, head of capital markets at LSEG, earlier told the Financial Times that the London-based exchange had been examining the potential for a blockchain-powered trading venue for around a year and had reached an "inflection point". (Blockchain, best known as the technology underpinning cryptocurrencies such as bitcoin and other crypto assets, is a digital ledger which records and verifies transactions.)
LSEG's move comes as a number of mainstream financial institutions are talking about the potential for blockchain to streamline the process of issuing and trading financial assets. "LSEG is exploring plans to build an end-to-end digital market ecosystem that will allow for the raising and transfer of capital in a more seamless, cost efficient way across asset classes."
Roos earlier told the FT in an interview that LSEG is definitely not building anything around cryptoassets, but is instead looking to use the technology to improve the efficiency of buying, selling and holding traditional assets. "The idea is to use digital technology to make a process that is slicker, smoother, cheaper and more transparent . . . and to have it regulated."
LSEG is considering a separate legal entity for the digital markets business; it hoped to have this running within a year, subject to regulatory approvals. The company is already in talks with regulators, multiple jurisdictions, as well as the British government and Treasury.
I do not believe that it is appropriate to blame the CEO for the Sprinter trial outcome. Didn’t RM state something about SNG001 “needing a fire to put out” following the P2 Home trial? Had the patient recruitment for the Sprinter trial included those with more severe symptoms, as RM implied, SNG001 might have had a better opportunity to demonstrate its effectiveness when compared with the placebo arm?
The “blame game” ended a long time ago. Those of us who remained invested, and in some cases added to our investment subsequently, are focused on the current strategy, and how it will evolve over the next year. Perhaps the company will give us an update this month? Dr. Monk’s recent article has serve to add to my optimism.
Pennsylvania. Sept 7- 8.
https://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/index.stm
Many thanks Fruitsnveg and Doc.Daneeka. You have both added a considerable amount of flesh to my bare bones of a prediction.
Additionally, the issue of the risks that are associated with these trials have been raised.
A partnership with a large bio pharmaceutical company would have enlarged the trial numbers, and correspondingly increased the chance of success. That may still happen later should Synairgen’s P2 trials provide the necessary data to satisfy our potential partners? The company have hinted that this is the case.
It will all hinge on whether Synairgen are able to recruit appropriate patient cohorts to deliver the necessary outcomes for these trials? An exciting albeit nervous time lies ahead for investors. I remain optimistic that the company may get their current strategy over the line by next Summer. One cannot think otherwise if one chooses to remain invested.
No Fruitsnveg. My prediction isn’t based on anything stated by the company, but partly on my own past experience as a scientific researcher.
As far as I can ascertain, Synairgen are currently in the process of designing their P2 trials, and will use data from a study carried out by Southampton’s Clinical Trials Unit to fine tune the process. We have been told that the trials are expected to commence during next Winter. Allowing for the time taken to conduct the trials, and process the data should take us through to next Spring at the earliest IMHO. I have been a Synairgen investor for three years, and know that the company will not rush through the process; nor will they issue any statements until they are certain of the outcomes.
When I add my own experience to my estimate, I know full well that a study can take far longer than was originally envisaged. In my own work, it took six months to identify and correct an error in the original experimental design to finally enable the process to produce meaningful and repeatable data. Synairgen’s past trials have similarly been affected by factors which were not accounted for in the design process. Although Synairgen’s study is very different from my experience, any scientific “experiment” can take longer than was originally envisaged to achieve an outcome.
My “prediction” may be widely inaccurate as I have no experience whatsoever in the bio-pharmaceutical sector. My very limited knowledge is based on my background knowledge in relation to this investment. I would be more than happy if you, or anyone else who is better informed than myself, could provide a more accurate estimate of the time that this particular study may take to complete.
Thank you for sharing the article SlamDunk1.
It is reassuring that Dr Monk continues to fight Synairgen’s corner. He has described the case for SNG001 as a broad spectrum antiviral treatment perfectly through working through the key points.
Unfortunately there are too many uninvested trolls on Synairgen bulletin boards, who regularly set out the same simplistic contra SNG001 arguments that they have been peddling for the last 18 months. It is exasperating when they “attack” investors’arguments in doing so, and I believe that they must have an ulterior motive, or else personal issues for doing so?
My own thinking has been aligned with the points set out by Dr. Monk for several months. Future progress will depend on the outcome of the most recent strategy set out by the company. It will take the best part of a year to complete the multiple P2 trials, and analyse, interpret and publish the outcomes. The severe lesson learned last year will have been noted, and the company will take the necessary measures to give these trials the best chance for a positive outcome.
There is little point in speculating what might happen should Synairgen be successful? My wish would be for the company to seek a partnership deal with a suitable bio pharmaceutical entity to take their therapy further. I look forward to hearing more from Synairgen concerning the P2 trials before the end of the current year.
I recently discovered Mrs Clarke’s updated LinkedIn profile when she gave a thumbs up to one of Rick Bright’s comments.
She describes herself as an “Experienced Corporate Affairs Leader” and her new position is Head of Communications at Norgine. Her announcement of her new position on LinkedIn got 201 “thumbs up” acknowledgements including three from the Synairgen executives, who were appointed at around the same time as Mrs. Clarke in 2021.
Mrs Clarke lists 14 skill areas under her Synairgen experience. It would appear that she was responsible for managing the website, and that the LinkedIn/ twitter carousel, which has now ceased, was also her initiative.
It is strange that the Synairgen LinkedIn branded messages rarely received double figures for their approval. The latter included regular thumbs ups from several Synairgen employees. Conversely, Mrs Clarke’s personal announcement received 20 times as many approvals as was achieved on average by her Synairgen messages.
Unfortunately, in today’s work environment the personality ethic has well overshadowed the work ethic. Apparently, there is more interest shown in the career development of an executive, than in developments that may affect the future prosperity of a company.
This weird phenomenon is also present on Synairgen bulletin boards, notably the indecipherable advfn board, where other contributors attract more attention than the company we are invested in? Perhaps these forums should be split in two, so that those of us who are predominately interested in discussing a company can focus on just that! Not that there is much to discuss at present as we continue to wait for a more detailed announcement about the start and nature of the forthcoming P2 trials.
Rick Bright’s tweet earlier today is relevant to this, and also applies to Southampton Clinical Trials Unit’s UNIVERSAL study, and to Synairgen’s forthcoming P2 trials.
Preparing for the spread of a seriously debilitating virus is more of a key issue than ever following our recent experiences. Synairgen’s plan on harvesting focused data is an essential part of the process :
“ It’s crucial that countries prioritise and invest in strengthening systems to report testing data. Efforts to establish centralised, coordinated, and connected reporting systems are important to ensure that we’re prepared and able to detect and respond to global health threats.
To achieve a rapid response to emerging pathogens ……,, we need to invest in decentralised molecular testing with real time centralised reporting capabilities to rapidly monitor risk and guide an effective response.” Rick Bright.